Please login to the form below
ledipasvir
This page shows the latest ledipasvir news and features for those working in and with pharma, biotech and healthcare.
Gilead wins European approval for triple hep C combination Vosevi
The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include
Latest news
-
Merck & Co pulls out of hepatitis C R&D as market shrinks
In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half
-
Gilead makes $11.9bn play for CAR-T specialist Kite
Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call
-
Gilead gets OK for three-in-one hep C therapy in US
Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and
-
Two new hepatitis C therapies fast-tracked in Europe
Sofosbuvir and velpatasvir are the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa, as a successor to its massively successful Harvoni (sofosbuvir/ledipasvir) but with activity
More from news
Approximately 4 fully matching, plus 62 partially matching documents found.
Latest Intelligence
-
AbbVie: New firm, new thinking
Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- May’s Brexit plan cautiously welcomed by biopharma sector
- Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Fishawack acquires brand communications agency Healthcircle
- Roche keeps Venclexta train rolling with new leukaemia filing
- Pfizer builds gap between pharma and consumer health units
PMHub
OPEN Access Consulting
OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...
Latest intelligence
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
- Creativity has lost its worth
- Creativity has lost its worth, and sadly it is undermining effectiveness...
Quick links
Infographics
